Holen Sie sich die Stockscreener-App
3.14
5.14%
-0.17
Handel nachbörslich:
3.13
-0.01
-0.32%
Schlusskurs vom Vortag:
$3.31
Offen:
$3.21
24-Stunden-Volumen:
5,515
Relative Volume:
0.07
Marktkapitalisierung:
$13.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.75M
KGV:
-0.9662
EPS:
-3.25
Netto-Cashflow:
$-30.91M
1W Leistung:
+11.35%
1M Leistung:
-17.37%
6M Leistung:
-31.89%
1J Leistung:
+992.55%
1-Tages-Spanne:
$3.14
$3.25
1-Wochen-Bereich:
$2.85
$3.42
52-Wochen-Spanne:
$0.23
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.14 | 14.03M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
Can Cellectar Biosciences Inc weather a recession2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
How cyclical is Cellectar Biosciences Inc.’s revenue streamQuarterly Portfolio Review & Accurate Entry/Exit Alerts - mfd.ru
Can Cellectar Biosciences Inc. disrupt its industryQuarterly Growth Report & Real-Time Volume Spike Alerts - mfd.ru
Risk Report: Is BioLineRx Ltd Depositary Receipt a top pick in the sectorInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Weekly Trades: Is Cellectar Biosciences Inc a top pick in the sector - baoquankhu1.vn
What’s the fair value of Cellectar Biosciences Inc. stock - mfd.ru
Stock Analysis: What is the Moat Score of NAMIJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Can Cellectar Biosciences Inc disrupt its industryJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
What catalysts could drive Cellectar Biosciences Inc. stock higherMarket Insider Reports & Low Risk Trading Ideas - Bollywood Helpline
Is Cellectar Biosciences Inc currently under institutional pressure2025 Earnings Impact & High Return Trade Guides - baoquankhu1.vn
Fundamentals Check: How volatile is Cellectar Biosciences Inc stockWeekly Gains Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Ideas Watch: How cyclical is Cellectar Biosciences Incs revenue streamWeekly Stock Analysis & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug Technicals: Does Cellectar Biosciences Inc have a sustainable dividendQuarterly Earnings Report & Smart Allocation Stock Reports - baoquankhu1.vn
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference - marketscreener.com
Cellectar Advances CLR 125 Into Early Breast Cancer Trial, Adding Depth to Its Radiotherapy Pipeline - TipRanks
Cellectar Biosciences to highlight strategic initiatives for 2026 - marketscreener.com
Cellectar Biosciences Outlines 2026 Strategic Plan and Regulatory Milestones for Iopofosine I 131 and CLR 125 at Biotech Showcase - Quiver Quantitative
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase ... - bdtonline.com
Cellectar Biosciences to Highlight Strategic Initiatives - GlobeNewswire
HOKA Comfort Guide: Is Cellectar Biosciences Inc. stock dividend yield sustainableWide Width Options & support options for steady strides - Улправда
How Cellectar Biosciences Inc. stock performs in rate cut cyclesWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - Улправда
Sentiment Review: What catalysts could drive Cellectar Biosciences Inc stock higherPortfolio Profit Report & Low Risk Entry Point Guides - Bộ Nội Vụ
ABTBiotech Stocks Forge Ahead With Confidence on This Week's Healthy Biotech Rally - ADVFN
Why retail investors favor Cellectar Biosciences Inc. stockStop Loss & Real-Time Buy Signal Notifications - Улправда
Momentum Shift: Will Cellectar Biosciences Inc. stock outperform value stocksMarket Performance Recap & Weekly High Conviction Trade Ideas - Улправда
Published on: 2026-01-09 06:04:32 - Улправда
Is Cellectar Biosciences Inc. stock ready for breakoutForecast Cut & High Yield Stock Recommendations - Улправда
Trend Report: What catalysts could drive Cellectar Biosciences Inc. stock higherWeekly Market Summary & Fast Entry Momentum Trade Alerts - Улправда
Bond Watch: Why retail investors favor Cellectar Biosciences Inc. stock2025 Volume Leaders & Weekly Momentum Stock Picks - Улправда
Is Cellectar Biosciences Inc. stock a buy before product launchesWeekly Loss Report & AI Forecast Swing Trade Picks - Улправда
Is Cellectar Biosciences Inc. stock attractive for retirement portfoliosJuly 2025 Sentiment & Proven Capital Preservation Methods - Улправда
Will Cellectar Biosciences Inc. stock beat EPS estimatesJuly 2025 Sector Moves & Community Verified Watchlist Alerts - Улправда
Why Cellectar Biosciences Inc. stock could rally in 2025Earnings Per Share Trends & Affordable Market Strategies - Улправда
Trade Report: Why Rezolve AI PLC stock appeals to dividend seekersWeekly Trading Summary & Fast Momentum Entry Tips - moha.gov.vn
What drives Cellectar Biosciences Inc stock priceHealthcare Stock Analysis & Affordable Growth Trading - earlytimes.in
Targets Report: Why retail investors favor Cellectar Biosciences Inc stockMarket Growth Review & Accurate Entry/Exit Alerts - moha.gov.vn
Layoff Watch: Will Cellectar Biosciences Inc stock outperform value stocksBond Market & Community Verified Trade Signals - Bộ Nội Vụ
Can Ahimsa Industries Limited Regain Momentum After BreakdownMarket Rumors and News & Affordable Stock Market Tips - earlytimes.in
Will Cellectar Biosciences Inc. stock reach Wall Street targets2025 Investor Takeaways & Real-Time Volume Spike Alerts - Улправда
How Cellectar Biosciences Inc. (NV4) stock reacts to weak economyJuly 2025 WrapUp & Smart Allocation Stock Reports - Bölüm Sonu Canavarı
Will Cellectar Biosciences Inc. stock benefit from sector rotation2025 Stock Rankings & Low Volatility Stock Suggestions - Улправда
Why Cellectar Biosciences Inc. stock remains undervaluedJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Aug Swings: Will Cellectar Biosciences Inc. stock reach Wall Street targets2025 Historical Comparison & Weekly Watchlist of Top Performers - ulpravda.ru
How Cellectar Biosciences Inc. stock trades before earningsJuly 2025 Volume & Low Risk Entry Point Tips - Улправда
Should I buy Cellectar Biosciences Inc. (NV4) stock before earnings seasonJuly 2025 Update & Real-Time Market Trend Scan - DonanımHaber
What MACD trends signal for Cellectar Biosciences Inc. (NV4) stock2025 Short Interest & Verified Momentum Stock Alerts - Улправда
Bond Watch: Why Cellectar Biosciences Inc. stock could rally in 2025July 2025 Setups & Momentum Based Trading Ideas - Улправда
Cellectar Biosciences announces supply agreement with Ionetix - MSN
Cellectar Biosciences, Inc. (CLRB) director John Neis reports stock sale - Stock Titan
Cellectar secures multi-year supply of alpha-emitting radioisotopes By Investing.com - Investing.com Australia
Cellectar Biosciences : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):